Registered title, quoted from ClinicalTrials.gov
Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular
An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Shandong Cancer Hospital and Institute; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07352007, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
BCLC 0-B.
Inclusion criterion 4
Child-Pugh score of ≤7.
Inclusion criterion 7
For female subjects of childbearing potential, a negative urine or serum pregnancy test must be confirmed within 3 days prior to receiving the first dose of the study drug (Cycle 1, Day 1). If a urine pregnancy test is inconclusive, a blood pregnancy test is required. Non-childbearing potential is defined as being post-menopausal for at least 1 year, or having undergone surgical sterilization or hysterectomy.
Inclusion criterion 15
If there is a risk of conception, all subjects (both male and female) must use highly effective contraceptive methods (with a failure rate of <1% per year) throughout the entire treatment period and for at least 120 days after the last dose of the study drug (or 180 days after the last dose of chemotherapy). Estimated life expectancy ≥12 weeks.
Inclusion criterion 16
Prior receipt of any systemic antitumor therapy for HCC, including treatment with antibodies such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 agents.
Exclusion criterion 4
Diagnosis of another malignancy within 5 years prior to the first dose, with the exception of radically treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or carcinoma in situ that has undergone radical resection. If another malignancy or HCC was diagnosed more than 5 years prior to the first dose, pathological or cytological confirmation is required for any recurrent or metastatic lesions.
Exclusion criterion 14
ECOG PS score of 0-1.
Inclusion criterion 3
At least one measurable lesion according to RECIST 1.1 or mRECIST criteria.
Inclusion criterion 12
History of any histologically/cytologically confirmed malignancy other than HCC.
Exclusion criterion 1
Acute or chronic active hepatitis B or C infection, defined as: Hepatitis B virus (HBV) DNA >2000 IU/mL or 10⁴ copies/mL; Hepatitis C virus (HCV) RNA >10³ copies/mL; Co-positive for Hepatitis B surface antigen (HBsAg) and anti-HCV antibody.
Exclusion criterion 5
Human Immunodeficiency Virus (HIV) infection (positive HIV 1/2 antibodies) or known active syphilis infection.
Exclusion criterion 7
Any local therapy for liver cancer received within 4 weeks prior to the first dose.
Exclusion criterion 13
Female patients who are pregnant or breastfeeding.
Exclusion criterion 17
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07352007, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Written informed consent must be provided and signed prior to the implementation of any trial-related procedures.
- Male or female subjects aged ≥18 years and ≤75 years.
- ECOG PS score of 0-1.
- BCLC 0-B.
- Diagnosed with HCC according to the diagnostic criteria of the Chinese Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2019 Edition).
- CNLC Stage IA-IIB.
- Child-Pugh score of ≤7.
- No prior systemic antitumor therapy for hepatocellular carcinoma.
- Assessed as suitable for R0 resection surgery.
- Assessed as having no contraindications to SBRT and immunotherapy.
- Estimated life expectancy of >3 months.
- At least one measurable lesion according to RECIST 1.1 or mRECIST criteria.
- Adequate organ and bone marrow function, defined as follows:a) Hematology: Absolute neutrophil count (ANC) ≥1.5×10⁹/L; Platelet count (PLT) ≥75×10⁹/L; Hemoglobin (HGB) ≥9.0 g/dL.b) Liver function: Serum total bilirubin (TBIL) ≤3 × upper limit of normal (ULN); Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤5 × ULN; Serum albumin ≥28 g/L.c) Renal function: Serum creatinine (Cr) ≤ 1.5 × ULN or creatinine clearance (CCr) ≥ 50 mL/min (Cockcroft-Gault formula); Urinalysis shows urine protein <2+; For patients with baseline urinalysis showing urine protein ≥2+, a 24-hour urine collection must demonstrate 24-hour urine protein <1 g.d) Coagulation function: International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
- For subjects with acute or chronic active hepatitis B or C infection, continuous antiviral therapy must be administered during the study period.
- For female subjects of childbearing potential, a negative urine or serum pregnancy test must be confirmed within 3 days prior to receiving the first dose of the study drug (Cycle 1, Day 1). If a urine pregnancy test is inconclusive, a blood pregnancy test is required. Non-childbearing potential is defined as being post-menopausal for at least 1 year, or having undergone surgical sterilization or hysterectomy.
- If there is a risk of conception, all subjects (both male and female) must use highly effective contraceptive methods (with a failure rate of <1% per year) throughout the entire treatment period and for at least 120 days after the last dose of the study drug (or 180 days after the last dose of chemotherapy). Estimated life expectancy ≥12 weeks.
Exclusion Criteria:
- History of any histologically/cytologically confirmed malignancy other than HCC.
- History of hepatic encephalopathy, or history of liver transplantation.
- Presence of any extrahepatic metastatic lesions.
- Prior receipt of any systemic antitumor therapy for HCC, including treatment with antibodies such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 agents.
- Acute or chronic active hepatitis B or C infection, defined as: Hepatitis B virus (HBV) DNA >2000 IU/mL or 10⁴ copies/mL; Hepatitis C virus (HCV) RNA >10³ copies/mL; Co-positive for Hepatitis B surface antigen (HBsAg) and anti-HCV antibody.
- Radiotherapy received within 3 weeks prior to the first dose.
- Human Immunodeficiency Virus (HIV) infection (positive HIV 1/2 antibodies) or known active syphilis infection.
- Severe infections that are either active or poorly controlled clinically.
- Active autoimmune disease that required systemic treatment within the past 2 years prior to the first dose.
- Known history of primary immunodeficiency. The presence of autoimmune antibodies alone requires the investigator's judgment to confirm the presence of an autoimmune disease.
- Use of immunosuppressive medication within 4 weeks prior to the first dose, with the exception of intranasal, inhaled, or other routes of locally administered corticosteroids, or systemic corticosteroids at physiological doses (i.e., not exceeding 10 mg/day prednisone or an equivalent dose of other corticosteroids). Temporary use of corticosteroids for conditions such as asthma or COPD for dyspnea is permitted.
- Administration of any live attenuated vaccine within 4 weeks prior to the first dose or planned administration during the study period.
- Any local therapy for liver cancer received within 4 weeks prior to the first dose.
- Diagnosis of another malignancy within 5 years prior to the first dose, with the exception of radically treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or carcinoma in situ that has undergone radical resection. If another malignancy or HCC was diagnosed more than 5 years prior to the first dose, pathological or cytological confirmation is required for any recurrent or metastatic lesions.
- Known allergy to any component of the Sintilimab formulation; or history of severe allergic reactions to other monoclonal antibodies or tyrosine kinase inhibitors.
- Treatment received as part of another clinical trial within 4 weeks prior to the first dose.
- Female patients who are pregnant or breastfeeding.
- Any other acute or chronic disease, psychiatric disorder, or abnormal laboratory test value that may lead to the following outcomes: increased risk associated with study participation or study drug administration, interference with the interpretation of study results, and based on the investigator's judgment, makes the patient unsuitable for participation in this study.
Quoted from ClinicalTrials.gov, NCT07352007, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07352007, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.